thank you. >> jarrod holtz of mezuho. so it's only a matter of a few years here in terms of full price. >> it's just interesting to bring it back to what the market does and what the investor community are willing to price and give the competitive advantage and for how long? on some level, it's the debate around nvidia and a couple of at least they were the bigger probably. but even if you think about this week when talking about the dynamics around, you know, the challenge to other drugs and this is a stock that ultimately didn't price in any of the competitiveness this week when you consider how important that drug is to the profile. in the short run, investors are staying long in the names. we've seen that. it is kind of, i can deal with 27 and 27. i don't see even the analyst pricing that in yet. >> i don't think there is a winner here. who is losing less? to tim's point, i think it is the incumbents losing less. they're making a decisionin on what is going to be going forward. >> coming up, time to face your fears. t